skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: tipo de recurso: Artigos de Jornal remover assunto: Immunotherapy remover assunto: Cancer remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
NIH-FUNDED CANINE IMMUNOTHERAPY DATA CENTER CHARTS A PATH TOWARD TRANSFORMATIVE THERAPIES
NIH-FUNDED CANINE IMMUNOTHERAPY DATA CENTER CHARTS A PATH TOWARD TRANSFORMATIVE THERAPIES
Material Type:
Artigo de Jornal 		Adicionar ao Meu Espaço

NIH-FUNDED CANINE IMMUNOTHERAPY DATA CENTER CHARTS A PATH TOWARD TRANSFORMATIVE THERAPIES

States News Service, 2022-10-18

States News Service

Sem texto completo

Citações Citado por
2
Eye-catching cancer drug trial results have researchers asking: What's next?
Eye-catching cancer drug trial results have researchers asking: What's next?
Material Type:
Artigo de Jornal 		Adicionar ao Meu Espaço

Eye-catching cancer drug trial results have researchers asking: What's next?

Washingtonpost.com, 2022-06-10

The Washington Post

Sem texto completo

Citações Citado por
3
MIT'S TOP RESEARCH STORIES OF 2021
MIT'S TOP RESEARCH STORIES OF 2021
Material Type:
Artigo de Jornal 		Adicionar ao Meu Espaço

MIT'S TOP RESEARCH STORIES OF 2021

States News Service, 2021-12-21

States News Service

Sem texto completo

Citações Citado por
4
DR. C. OLA LANDGREN HONORED WITH THE PAUL J. DIMARE ENDOWED CHAIR IN IMMUNOTHERAPY
DR. C. OLA LANDGREN HONORED WITH THE PAUL J. DIMARE ENDOWED CHAIR IN IMMUNOTHERAPY
Material Type:
Artigo de Jornal 		Adicionar ao Meu Espaço

DR. C. OLA LANDGREN HONORED WITH THE PAUL J. DIMARE ENDOWED CHAIR IN IMMUNOTHERAPY

States News Service, 2021-11-09

States News Service

Sem texto completo

Citações Citado por
5
INTERVIEW WITH YEVGENIY SEMENOV, MD: CUTANEOUS IMMUNE-RELATED ADVERSE EVENTS
INTERVIEW WITH YEVGENIY SEMENOV, MD: CUTANEOUS IMMUNE-RELATED ADVERSE EVENTS
Material Type:
Artigo de Jornal 		Adicionar ao Meu Espaço

INTERVIEW WITH YEVGENIY SEMENOV, MD: CUTANEOUS IMMUNE-RELATED ADVERSE EVENTS

States News Service, 2021-06-08

States News Service

Sem texto completo

Citações Citado por
6
3.35M GOING TO CANCER RESEARCH AT DARTMOUTH-HITCHCOCK - ASSOCIATED PRESS
3.35M GOING TO CANCER RESEARCH AT DARTMOUTH-HITCHCOCK - ASSOCIATED PRESS
Material Type:
Artigo de Jornal 		Adicionar ao Meu Espaço

3.35M GOING TO CANCER RESEARCH AT DARTMOUTH-HITCHCOCK - ASSOCIATED PRESS

States News Service, 2021-02-07

States News Service

Sem texto completo

Citações Citado por
7
GEMoaB and Intellia Therapeutics Enter into Research Collaboration and Licensing Agreement on Next-Generation Cellular Immunotherapy Based on Proprietary RevCAR and CRISPR/Cas9 Genome Editing Platforms
GEMoaB and Intellia Therapeutics Enter into Research Collaboration and Licensing Agreement on Next-Generation Cellular Immunotherapy Based on Proprietary RevCAR and CRISPR/Cas9 Genome Editing Platforms
Material Type:
Artigo de Jornal 		Adicionar ao Meu Espaço

GEMoaB and Intellia Therapeutics Enter into Research Collaboration and Licensing Agreement on Next-Generation Cellular Immunotherapy Based on Proprietary RevCAR and CRISPR/Cas9 Genome Editing Platforms

PR newswire, 2020-07-20

PR Newswire Association LLC

Sem texto completo

Citações Citado por
8
TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma
TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma
Material Type:
Artigo de Jornal 		Adicionar ao Meu Espaço

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma

Marketwired, 2023-01-31

Marketwire L.P., by its general partner Marketwire Canada Limited

Sem texto completo

Citações Citado por
9
OncoSec presents encouraging early data with TAVO(TM)-EP combined with nivolumab (Opdivo) in neoadjuvant melanoma
OncoSec presents encouraging early data with TAVO(TM)-EP combined with nivolumab (Opdivo) in neoadjuvant melanoma
Material Type:
Artigo de Jornal 		Adicionar ao Meu Espaço

OncoSec presents encouraging early data with TAVO(TM)-EP combined with nivolumab (Opdivo) in neoadjuvant melanoma

PR newswire, 2022-11-15

PR Newswire Association LLC

Sem texto completo

Citações Citado por
10
ANDREW MCSHAN AWARDED CURCI GRANT FOR CUTTING-EDGE CANCER RESEARCH
ANDREW MCSHAN AWARDED CURCI GRANT FOR CUTTING-EDGE CANCER RESEARCH
Material Type:
Artigo de Jornal 		Adicionar ao Meu Espaço

ANDREW MCSHAN AWARDED CURCI GRANT FOR CUTTING-EDGE CANCER RESEARCH

States News Service, 2024-03-25

States News Service

Sem texto completo

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Recursos Online (1)

Data de Publicação 

De até
Refinar
  1. Antes de2011  (14)
  2. 2011Até2013  (38)
  3. 2014Até2016  (82)
  4. 2017Até2020  (192)
  5. Após 2020  (291)
  6. Mais opções open sub menu

Base de Dados/Biblioteca 

  1. Academic OneFile  (616)
  2. Regional Business News - EBSCO  (398)
  3. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.